Globus Medical, Inc. (NYSE: GMED ) reported second-quarter 2024 adjusted earnings per share of 75 cents, which beat the Zacks Consensus Estimate by 10.3%. The figure increased 19% year over year. The adjusted EPS excludes certain non-recurring expenses and benefits, such as the amortization of intangibles, merger and acquisition-related costs/licensing and provision for litigation, among others. Without adjustments, the company registered a GAAP diluted EPS of 23 cents, down 59.6% from the year-ago quarter''s figure. Revenues Worldwide sales increased a staggering 115.9% year over year to $629.7 million. The reported figure exceeded the Zacks Consensus Estimate by 2.4%. Net sales improvement was driven by the addition of NuVasive, as well as increased volumes of spine product sales and Enabling Technology products and services. Geographic Details Net sales generated in the United States increased 103.5% year over year (same at CER) to $499.5 million. Our model projected a 103.8% improvement in sales from this region.

https://www.investing.com/news/company-news/truist-raises-globus-medical-stock-target-maintains-hold-rating-on-consistent-growth-93CH-3558827

Globus Medical Inc (GMED) Q2 2024 Earnings Call Transcript Highlights: Record Growth and Strategic Insights

Globus Medical, Inc. (NYSE:NYSE:GMED) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ETCompany ParticipantsBrian Kearns - SVP, Business Development…

GMED earnings call for the period ending June 30, 2024.

Globus Medical reports 115.9% Q2 sales surge to $629.7M, driven by NuVasive acquisition. Despite revenue growth, GAAP income drops 45%. Learn about the medical device giant''s mixed results and raised 2024 guidance.

Globus Medical''s (NYSE: GMED ) short percent of float has fallen 4.92% since its last report. The company recently reported that it has 6.80 million shares sold short , which is 6.77% of all regular shares that are available for trading. Based on its trading volume, it would take traders 10.57 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price … Full story available on Benzinga.com

Globus Medical (GMED) said it has received FDA clearances for its ExcelsiusFlex with Total Knee Arthroplasty and ACTIFY 3D Total Knee implant system. Read more here.

Globus Medical receives FDA clearance for ExcelsiusFlex™ and ACTIFY™ 3D Total Knee System. Discover how these innovative solutions are advancing knee arthroplasty procedures and improving patient outcomes.

AUDUBON, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Globus Medical , Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the second quarter ended June 30, 2024 after the market close on Tuesday, August 6, 2024. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com .